<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Site da Brakke Consulting</provider_name><provider_url>https://brakkeconsulting.com/pt</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="UYUa6D0aPT"&gt;&lt;a href="https://brakkeconsulting.com/pt/22111/"&gt;Not&#xED;cias e notas sobre sa&#xFA;de animal de 8 de fevereiro de 2002&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/pt/22111/embed/#?secret=UYUa6D0aPT" width="600" height="338" title="&#x201C;Animal Health News &amp; Notes for February 8, 2002&#x201D; &#x2014; Brakke Consulting Website" data-secret="UYUa6D0aPT" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>&nbsp;**************************************************************** Brakke Consulting&rsquo;s Animal Health News &amp; Notes for February 8, 2002 Copyright &copy; Brakke Consulting, Inc. **************************************************************** Company Earnings Releases &gt;&nbsp; Novartis reported that sales for its animal health division for the full year 2001 were CHF 962 million ($573 million) a decrease of 7% from the prior year.&nbsp; Sales were affected by the economic slowdown and substantial inventory reductions at US companion animal veterinary clinics, as well as the impact of foot-and-mouth disease in the UK.&nbsp; Most other European countries reported good performances, as did Latin America and the Asia/Pacific region.&nbsp; Sales were lifted by the strongly growing vaccine and aquaculture businesses, and by sales of Tiamutin and Fortekor, the last posting double-digit growth. (company press release) &gt;&nbsp; Pharmacia reported that sales for its animal health division for the fourth quarter 2001 were $125 million, a 7% increase over the comparable period in 2000.&nbsp; Sales for the year were $469 million, an increase of 6% over the year 2000.&nbsp; The increase in sales for the fourth quarter 2001 was led by the strong performance of the injectable antibiotic brands, Naxcel/Excenel.&nbsp; For the full year, the Naxcel/Excenel brands led the business&rsquo; growth, supported by strong contributions from the mastitis product line which includes the J-5 Vaccine.&nbsp; (company press release) &gt;&nbsp; Virbac S.A. reported growth of 7.6% to reach 350View Full Post;</description></oembed>
